Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg
qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or
refractory ovarian cancer compared with weekly paclitaxel (80 mg/m2, d1, d8, d15, q3w).